TELA Bio, Inc.
NASDAQ:TELAMedical - Devices
+$0.09 today
- Market cap
- $51.00M
- Beta
- 1.36
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.72
Volume 0.22M
Average 0.17M
TELA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
TELA Bio, Inc.NASDAQ: TELA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$9.03M, compared with -$8.43M a year earlier. Trailing-twelve-month EBITDA was -$33.12M.
Context
- EBITDA amounted to 40.3% of revenue in FY2025, down 5.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$25.45M (+21.3%) for the fiscal year ending Dec 2026, a step up from the -2.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$9.03M+8.7% QoQ
- Last fiscal yearDec 2025
- -$32.35M-2.1% YoY
- LTMJun 2026
- -$33.12M+4.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -7.1% | -15.6% | -8.5 pp |
| 1 year | -2.1% | +21.3% | +23.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (32.35M) USD
- Year-over-year change
- -2.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.35M) | -2.1% |
| FY2024 | 2024-12-31 | (31.68M) | +22.0% |
| FY2023 | 2023-12-31 | (40.63M) | -4.0% |
| FY2022 | 2022-12-31 | (39.06M) | -34.0% |
| FY2021 | 2021-12-31 | (29.14M) | — |
EBITDA vs competitors
How TELA compares with its peers on the latest reported figures
- TELA's LTM Jun 2026 EBITDA of -$33.12M is the 7th highest of the 9 companies compared; the peer median is -$17.39M.
- Its year-over-year change of +4.6% is the 3rd highest of 9, against a peer median of -25.0%.
- EBITDA amounts to 41.4% of revenue for TELA, versus a peer median of 422.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$8.01M | -304.4% | — | 35.5% | |
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
MDAISpectral AI, Inc. | LTM Mar 2026 | -$12.72M | -139.2% | — | 76.2% |
| LTM Mar 2026 | -$15.84M | +57.4% | — | 48.4% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
| LTM Jun 2026 | -$33.12M | +4.6% | — | 41.4% | |
| LTM Mar 2026 | -$36.2M | +34.4% | — | — | |
| LTM Mar 2026 | -$62.08M | -482.8% | — | 18634.1% | |
| Peer median (excluding TELA) | -$17.39M | -25.0% | — | 422.6% | |
Competitors are the stored peer set for TELA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.46M | 41.42M | 58.45M | 69.3M | 80.28M |
| Cost of Revenue | 10.65M | 14.37M | 18.34M | 22.81M | 25.93M |
| Gross Profit | 18.81M | 27.04M | 40.11M | 46.49M | 54.34M |
| Gross Margin | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Research & Development | 6.74M | 8.94M | 9.62M | 8.81M | 9.22M |
| Selling, General & Admin | 41.52M | 57.11M | 74.57M | 79.37M | 78.88M |
| Operating Expenses | 48.26M | 66.05M | 84.19M | 80.6M | 88.1M |
| Depreciation & Amortization | 535K | 1.19M | 808K | 1.01M | 1.01M |
| EBITDA | (29.14M) | (39.06M) | (40.63M) | (31.68M) | (32.35M) |
| EBITDA Margin | -98.9% | -94.3% | -69.5% | -45.7% | -40.3% |
| Operating Income | (29.45M) | (39.01M) | (44.08M) | (34.12M) | (33.76M) |
| Operating Margin | -100.0% | -94.2% | -75.4% | -49.2% | -42.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.6M | 4.05M | 5.22M | 5.29M | 5.25M |
| Other Income / Expenses | (3.83M) | (5.29M) | (2.59M) | (3.87M) | (4.85M) |
| Income Before Tax | (33.28M) | (44.3M) | (46.66M) | (37.99M) | (38.6M) |
| Pre-Tax Margin | -112.9% | -106.9% | -79.8% | -54.8% | -48.1% |
| Income Tax Expense | 0 | 0 | 0 | (144K) | 230K |
| Net Income | (33.28M) | (44.3M) | (46.66M) | (37.84M) | (38.83M) |
| Net Margin | -112.9% | -106.9% | -79.8% | -54.6% | -48.4% |
| EPS (Basic) | (2.30) | (2.73) | (2.04) | (1.33) | (0.83) |
| EPS (Diluted) | (2.30) | (2.73) | (2.04) | (1.33) | (0.83) |
| Weighted Avg Shares | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M |
| Weighted Avg Shares (Diluted) | 14.47M | 16.27M | 22.87M | 28.53M | 46.95M |
TELA Bio, Inc.
NASDAQ:TELA
Intrinsic Alpha fair value
Locked
Current Price
$1.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.